BioSpace News Archive

Vistagen and Fuji Pharma Co., Ltd. announced they have entered into a time-limited agreement to negotiate exclusively with each other regarding a potential license to develop and commercialize Vistagen’s PH80 in Japan, including for the acute treatment of moderate to severe vasomotor symptoms due to menopause and potentially other indications.

Alvotech announced that Faysal Kalmoua has been appointed Alvotech’s Chief Operating Officer and Hafrun Fridriksdottir is stepping down following resubmission of the Biologics License Application for AVT02, Alvotech’s proposed high-concentration interchangeable biosimilar to Humira®.

Techsomed Ltd. announced today that it has received 510(k) clearance from the USA Food and Drug Administration (FDA) for its VisAble.IO software intended to assist physicians in planning liver ablation procedures, and confirming ablation zones, with the goal of increasing treatment precision.

The occurrence of neurological adverse events following COVID vaccines is generally acknowledged, but their significance is downplayed, writes Jane Orient, M.D., in the fall issue of the Journal of American Physicians and Surgeons.

Trethera Corporation announced the appointment of Michael Levy, MD, PhD, to its Scientific Advisory Board.

Zerion Pharma A/S (“ZERION”) today announces that the Company has strengthened its management team with the appointment of Dr. Mads Aaboe Jensen

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023, held at the Lotte New York Palace Hotel in New York City.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Communications Officer Will Roberts will provide a corporate presentation on September 12, 2023, at 9:30 AM EDT during the H.C. Wainwright 25th Annual Global Investment Conference.

iOmx Therapeutics AG (iOmx), a clinical stage biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the appointment of Dr. Nils Peter Debus as Chief Business Officer

EarliTec Diagnostics, Inc. (“EarliTec”) today announced that The Journal of the American Medical Association (JAMA) published positive results from a Phase III trial demonstrating that its EarliPointTM Evaluation can effectively and accurately aid in diagnosing and assessing autism in children as young as 16 to 30 months old.